Search Result
Results for "
FXR
" in MedChemExpress (MCE) Product Catalog:
10
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-151481
-
|
FXR
|
Metabolic Disease
|
FXR antagonist 1 (compound F6) is an orally active and selective intestinal FXR antagonist (IC50=2.1 μM). FXR antagonist 1 selectively inhibits intestinal FXR signalling through antagonism of intestinal FXR and feedback activation of hepatic FXR to improve hepatic steatosis, inflammation and fibrosis in NASH (nonalcoholic steatohepatitis) models. FXR antagonist 1 can be used in NASH studies .
|
-
-
- HY-153525
-
-
-
- HY-151932
-
|
FXR
|
Inflammation/Immunology
|
FXR agonist 3 is an anti-NASH agent, acting by activating FXR. FXR agonist 3 inhibits COL1A1, TGF-β1, α-SMA and TIMP1 expression with anti-fibrogenic activity. FXR agonist 3 significantly reduces liver steatosis and inflammation, improves liver fibrosis level .
|
-
-
- HY-148874
-
|
FXR
|
Metabolic Disease
|
FXR antagonist 2 (compound A-26) is a diarylamide derivative, as well as a moderate FXR antagonist. FXR antagonist 2 can be used in the study of hyperlipidemia and type 2 diabetes .
|
-
-
- HY-151959
-
|
FXR
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
FXR agonist 4 (compound 10a) is an agonist of farnesoid X receptor (FXR) with an EC50 value of 1.05 μM. FXR agonist 4 effectively improves hyperlipidemia, hepatic steatosis, insulin resistance and hepatic inflammation in DIO mice. FXR agonist 4 can be used for the research of non-alcoholic fatty liver disease (NAFLD) .
|
-
-
- HY-50911
-
FXR-450; XL335; WAY-362450
|
FXR
Autophagy
|
Metabolic Disease
Cancer
|
Turofexorate isopropyl (FXR-450) is a potent, selective, and orally bioavailable FXR agonist with EC50 of 4 nM .
|
-
-
- HY-163072
-
|
FXR
|
Metabolic Disease
|
FXR antagonist 3 (V02-8) is an intestine-specific farnesoid X receptor (FXR) antagonist, with an IC50 of 0.89 μM .
|
-
-
- HY-142159
-
-
-
- HY-RS05163
-
|
Small Interfering RNA (siRNA)
|
Others
|
FXR1 Human Pre-designed siRNA Set A contains three designed siRNAs for FXR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
FXR1 Human Pre-designed siRNA Set A
FXR1 Human Pre-designed siRNA Set A
-
- HY-RS05164
-
|
Small Interfering RNA (siRNA)
|
Others
|
FXR2 Human Pre-designed siRNA Set A contains three designed siRNAs for FXR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
FXR2 Human Pre-designed siRNA Set A
FXR2 Human Pre-designed siRNA Set A
-
- HY-151481A
-
|
FXR
|
Neurological Disease
|
β-FXR antagonist 1 (C 12), an isomer of FXR antagonist 1 (HY-151481) is a FXR antagonist .
|
-
-
- HY-125996
-
|
FXR
|
Inflammation/Immunology
|
NR1H4 activator 1 is a potent and selective Famesoid X Receptor (FXR) agonist, extracted from patent WO2018152171A1, example 4. NR1H4 activator 1 shows strong FXR agonistic potency with a EC50 value of 1 nM in a Human FXR (NR1H4) Assay. NR1H4 activator 1 has the potential for treatment of gastrointestinal disease .
|
-
-
- HY-163071
-
|
FXR
|
Metabolic Disease
|
V023-9340 is a potent FXR inhibitor with IC50 of 4.27 μM that can be used in NASH (nonalcoholic steatohepatitis) research .
|
-
-
- HY-149971
-
|
FXR
|
Inflammation/Immunology
|
XJ02862-S2 shows potent FXR agonistic activity. XJ02862-S2 is a promising lead compound for the research of NAFLD .
|
-
-
- HY-113567
-
|
FXR
|
Metabolic Disease
|
GSK2324 (Compd 1c) is a FXR agonist for diabetes study, with an EC50 of 120 nM. GSK2324 exhibits t1/2 values of 84 min (mouse), 170 min (rat), 110 min (beagle) and 120 min (cyno), respectively .
|
-
-
- HY-149831
-
|
FXR
|
Metabolic Disease
|
ZLY28 is the first-in-class intestinal restricted and orally active FXR and FABP1 dual modulator. ZLY28 also is a novel anti-NASH agent. ZLY28 can be used for the research of nonalcoholic steatohepatitis (NASH) .
|
-
-
- HY-139562
-
|
FXR
|
Metabolic Disease
|
BMS-986318 is a potent nonbile acid FXR agonist with EC50s of 53 and 350 nM in the FXR Gal4 and SRC-1 recruitment assays, respectively. BMS-986318 has a suitable ADME profile, and demonstrates efficacy in the mouse bile duct ligation model of liver cholestasis and fibrosis.BMS-986318 can be used for the research of nonalcoholic steatohepatitis .
|
-
-
- HY-100443B
-
(-)-PX-102 (trans isomer); (-)-PX-104
|
FXR
Autophagy
|
Metabolic Disease
|
(-)-PX20606 trans isomer is a FXR agonist with EC50s of 18 and 29 nM for FXR in FRET and M1H assay, respectively.
|
-
-
- HY-100443A
-
trans-PX-102
|
FXR
Autophagy
|
Metabolic Disease
|
PX20606 trans racemate (PX-102 trans racemate) is a FXR agonist with EC50s of 32 and 34 nM for FXR in FRET and M1H assay, respectively .
|
-
-
- HY-138937
-
|
FXR
|
Metabolic Disease
|
NDB is a selective human FXRα (hFXRα) antagonist that is effective in modulating transcription of FXRα downstream genes. NDB can be used in anti-diabetes research .
|
-
-
- HY-50108A
-
-
-
- HY-50108
-
-
-
- HY-N3209
-
-
-
- HY-134988
-
|
FXR
Phosphatase
Cytochrome P450
|
Inflammation/Immunology
|
EDP-305 is an orally active, potent and selective farnesoid X receptor (FXR) agonist, with EC50 values of 34 nM (chimeric FXR in CHO cells) and 8 nM (full-length FXR in HEK cells). EDP-305 shows a potent and consistent antifibrotic effect. EDP-305 can be used for primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH) research .
|
-
-
- HY-103704
-
-
-
- HY-110267
-
|
FXR
|
Metabolic Disease
|
DY268 is a farnesoid X receptor (FXR) antagonist (IC50=7.5 nM). It inhibits FXR transactivation in a cell-based assay with an IC50 value of 468 nM. DY268 can be used in the study of drug-induced liver injury (DILI) .
|
-
-
- HY-76847
-
-
-
- HY-107418
-
-
-
- HY-N3891
-
-
-
- HY-76847A
-
-
-
- HY-135400
-
|
FXR
|
Inflammation/Immunology
|
Glyco-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is a farnesoid X receptor (FXR) agonist .
|
-
-
- HY-14908
-
4sc-101; SC12267
|
Dihydroorotate Dehydrogenase
Interleukin Related
FXR
|
Infection
Inflammation/Immunology
|
Vidofludimus is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus also can be used for the research of fatty liver by targeting FXR .
|
-
-
- HY-122338
-
|
FXR
|
Metabolic Disease
|
Fexarine is a potent, non-steroidal and selective agonist of farnesoid X receptor (EC50: 38 nM). Fexarine can be used for the research of diseases linked to cholesterol, bile acids .
|
-
-
- HY-135399
-
|
FXR
|
Inflammation/Immunology
|
Tauro-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an orally bioavailable farnesoid-X receptor (FXR) agonist .
|
-
-
- HY-101273
-
-
-
- HY-109096
-
LMB763
|
FXR
Autophagy
|
Inflammation/Immunology
|
Nidufexor (LMB763) is an orally-available farnesoid X receptor (FXR) agonist for the research of nonalcoholic steatohepatitis (NASH) .
|
-
-
- HY-147296
-
-
-
- HY-14908A
-
4sc-101 hemicalcium; SC12267 hemicalcium
|
Dihydroorotate Dehydrogenase
Interleukin Related
FXR
|
Infection
Inflammation/Immunology
|
Vidofludimus (4sc-101; SC12267) hemicalcium is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus hemicalcium, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus hemicalcium also can be used for the research of fatty liver by targeting FXR .
|
-
-
- HY-76847S
-
-
-
- HY-76847S1
-
-
-
- HY-76847S2
-
-
-
- HY-76847S3
-
-
-
- HY-135103
-
T-βMCA sodium
|
FXR
|
Cancer
|
Tauro-β-muricholic Acid sodium (T-βMCA sodium), a endogenous metabolite, is a competitive and reversible farnesoid X receptor (FXR) antagonist, with an IC50 of 40 μM .
|
-
-
- HY-12434
-
-
-
- HY-114392
-
|
FXR
Autophagy
|
Metabolic Disease
|
Gly-β-MCA, a bile acid, is a potent, sable, intestine-selective and oral bioactive farnesoid X receptor (FXR) inhibitor that may be a candidate for the treatment of metabolic disorders .
|
-
-
- HY-76847R
-
CDCA (Standard)
|
FXR
Endogenous Metabolite
Autophagy
|
Metabolic Disease
Cancer
|
Chenodeoxycholic Acid (Standard) is the analytical standard of Chenodeoxycholic Acid. This product is intended for research and analytical applications. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.
|
-
-
- HY-B0172
-
-
-
- HY-N0805
-
23-Acetylalismol B; 23-O-Acetylalisol B; Alisol B monoacetate
|
Apoptosis
|
Others
|
Alisol B 23-acetate (23-Acetylalismol B), a natural triterpenoid, produces protective effects against EE-induced cholestasis, due to FXR-mediated gene regulation.
|
-
-
- HY-135400S
-
|
FXR
|
Inflammation/Immunology
|
Glyco-obeticholic acid-d5 is the deuterium labeled Glyco-Obeticholic acid. Glyco-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is a farnesoid X receptor (FXR) agonist[1].
|
-
-
- HY-135399S
-
|
FXR
|
Inflammation/Immunology
|
Tauro-obeticholic acid-d5 sodium is deuterium labeled Tauro-obeticholic acid. Tauro-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an orally bioavailable farnesoid-X receptor (FXR) agonist.
|
-
- HY-12222
-
INT-747; 6-ECDCA; 6-Ethylchenodeoxycholic acid
|
FXR
Autophagy
|
Others
|
Obeticholic acid (INT-747) is a potent, selective and orally active FXR agonist with an EC50 of 99 nM. Obeticholic acid has anticholeretic and anti-inflammation effect. Obeticholic acid also induces autophagy .
|
-
- HY-109197
-
EYP001
|
FXR
HBV
|
Infection
|
Vonafexor (EYP001) is an orally active, non-steroidal and selective FXR agonist. Vonafexor shows significant HBsAg reduction when combined with Peg-IFNα. Vonafexor can be used for anti-HBV research .
|
-
- HY-133890A
-
T-α-MCA sodium
|
Endogenous Metabolite
FXR
|
Others
|
Tauro-α-muricholic acid (T-α-MCA) sodium is a FXR (Farnesoid X receptor) antagonist (IC50=28μM). Tauro-α-muricholic acid sodium is also a endogenous metabolite that can be found in cecal .
|
-
- HY-10912
-
|
FXR
Autophagy
|
Others
|
Fexaramine is a potent and selective FXR agonist with an EC50 of 25 nM. Fexaramine has no activity against hRXRα, hPPARαγδ, mPXR, hPXR, hLXRα, hTRβ, hRARβ, mCAR, mERRγ, and hVDR receptors .
|
-
- HY-N4063
-
|
FXR
|
Inflammation/Immunology
|
Hedragonic acid is an oleane-type triterpenoid compound, which can be isolated from the stems and roots of the southern snake vine. Hedragonic acid is a ligand and agonist for FXR. Hedragonic acid protected mice from liver damage caused by acetaminophen overdose and reduced liver inflammation .
|
-
- HY-107738
-
Z/E-Guggulsterone
|
Apoptosis
JNK
Akt
Caspase
FXR
Autophagy
|
Cancer
|
Guggulsterone is a plant sterol derived from the gum resin of the tree Commiphora wightii. Guggulsterone inhibits the growth of a wide variety of tumor cells and induces apoptosis through down regulation of antiapoptotic gene products (IAP1, xIAP, Bfl-1/A1, Bcl-2, cFLIP and survivin), modulation of cell cycle proteins (cyclin D1 and c-Myc), activation of caspases and JNK, inhibition of Akt . Guggulsterone, a farnesoid X receptor (FXR) antagonist, decreases CDCA-induced FXR activation with IC50s of 17 and 15 μM for Z- and E-Guggulsterone, respectively .
|
-
- HY-109083
-
GS-9674
|
FXR
Autophagy
|
Inflammation/Immunology
|
Cilofexor (GS-9674) is a potent, selective and orally active nonsteroidal FXR agonist with an EC50 of 43 nM. Cilofexor has anti-inflammatory and antifibrotic effects. Cilofexor has the potential for primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH) research .
|
-
- HY-N10640
-
|
FXR
|
Inflammation/Immunology
|
Alismanol M is a farnesoid X receptor (FXR) agonist with an EC50 value of 50.25 μM. Alismanol M is a protostane-type triterpenoid that can be isolated from the rhizome of Alisma orientale. Alismanol M can be used for the research of cholestasis and nonalcoholic steatohepatitis .
|
-
- HY-135103S
-
|
FXR
|
Cancer
|
Tauro-β-muricholic acid-d4 (sodium) is the deuterium labeled Tauro-β-muricholic acid sodium. Tauro-β-muricholic Acid sodium (T-βMCA sodium), a endogenous metabolite, is a competitive and reversible farnesoid X receptor (FXR) antagonist, with an IC50 of 40 μM[1][2][3].
|
-
- HY-12222S
-
INT-747-d5; 6-ECDCA-d5; 6-Ethylchenodeoxycholic acid-d5
|
FXR
Autophagy
|
Others
|
Obeticholic acid-d5 is the deuterium labeled Obeticholic acid. Obeticholic acid (INT-747) is a potent, selective and orally active FXR agonist with an EC50 of 99 nM. Obeticholic acid has anticholeretic and anti-inflammation effect. Obeticholic acid also induces autophagy[1][2][3].
|
-
- HY-12222S1
-
|
FXR
Autophagy
|
Others
|
Obeticholic Acid-d4 is the deuterium labeled Obeticholic acid. Obeticholic acid (INT-747) is a potent, selective and orally active FXR agonist with an EC50 of 99 nM. Obeticholic acid has anticholeretic and anti-inflammation effect. Obeticholic acid also induces autophagy[1][2][3].
|
-
- HY-121238
-
|
Others
|
Metabolic Disease
|
Hyocholic Acid is a bile acid found in pig. Hyocholic Acid can also be found in urine samples from patients with cholestasis. Hyocholic Acid promotes GLP-1 secretion via activating TGR5 and inhibiting FXR in enteroendocrine cells. Hyocholic Acid is known for its exceptional resistance to type 2 diabetes .
|
-
- HY-N9933
-
TβMCA
|
FXR
Apoptosis
|
Metabolic Disease
Cancer
|
Tauro-β-muricholic acid (TβMCA) is a trihydroxylated bile acid. Tauro-β-muricholic acid is a competitive and reversible FXR antagonist (IC50 = 40 μM). Tauro-β-muricholic acid has antiapoptotic effect. Tauro-β-muricholic acid inhibits bile acid-induced hepatocellular apoptosis by maintaining the mitochondrial membrane potential .
|
-
- HY-150787
-
|
FXR
Cytochrome P450
|
Metabolic Disease
|
BMS-986339 is an orally active, potent FXR agonist. BMS-986339 forms H-bond with His298 and ASN287 residues. BMS-986339 can be used in the research of primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH), anti-fibrosis .
|
-
- HY-10626
-
|
LXR
FXR
ROR
Apoptosis
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
T0901317 is an orally active and highly selective LXR agonist with an EC50 of 20 nM for LXRα . T0901317 activates FXR with an EC50 of 5 μM . T0901317 is RORα and RORγ dual inverse agonist with Ki values of 132 nM and 51 nM, respectively . T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice .
|
-
- HY-110066
-
|
Apoptosis
VEGFR
Akt
Angiotensin-converting Enzyme (ACE)
SARS-CoV
FXR
|
Cancer
|
(Z)-Guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, inhibits the growth of human prostate cancer cells by causing apoptosis. (Z)-Guggulsterone inhibits angiogenesis by suppressing the VEGF–VEGF-R2–Akt signaling axis . (Z)-Guggulsterone is also a potent FXR antagonist. (Z)-Guggulsterone reduces ACE2 expression and SARS-CoV-2 infection .
|
-
- HY-15371
-
Forskolin
Maximum Cited Publications
94 Publications Verification
Coleonol; Colforsin; HL 362
|
Organoid
Adenylate Cyclase
FXR
Autophagy
PKC
|
Metabolic Disease
Inflammation/Immunology
Endocrinology
Cancer
|
Forskolin (Coleonol) is a potent adenylate cyclase activator with an IC50 of 41 nM and an EC50 of 0.5 μM for type I adenylyl cyclase . Forskolin is also an inducer of intracellular cAMP formation . Forskolin induces differentiation of various cell types and activates pregnane X receptor (PXR) and FXR . Forskolin exerts a inotropic effect on the heart, and has platelet antiaggregatory and antihypertensive actions. Forskolin also induces autophagy .
|
-
- HY-153114
-
|
FXR
|
Inflammation/Immunology
|
HEC96719 is a selective and orally active tricyclic farnesoid X receptor (FXR) agonist with EC50 values of 1.37 and 1.55 nM by time-resolved fluorescence energy transfer (TR-FRET) and luciferase reporter assays, respectively. HEC96719 significantly improves non-alcoholic steatohepatitis (NASH) and liver fibrosis with favorable tissue distribution in liver and intestine. HEC96719 can be used for the research of non-alcoholic steatohepatitis .
|
-
- HY-100277
-
SR-202
|
PPAR
|
Metabolic Disease
|
Mifobate (SR-202) is a potent and specific PPARγ antagonist. Mifobate (SR-202) selectively inhibits Thiazolidinedione (TZD)-induced PPARγ transcriptional activity (IC50=140 μM). Mifobate (SR-202) does not affect basal or ligand-stimulated transcriptional activity of PPARα, PPARβ, or the farnesoid X receptor (FXR). Mifobate (SR-202) shows antiobesity and antidiabetic effects .
|
-
- HY-163436
-
|
FXR
Cytochrome P450
RAR/RXR
PPAR
ROR
|
Metabolic Disease
|
F44-A13 is an orally active and highly selective farnesoid X receptor (FXR) antagonist with an IC50 value of 1.1 μM. F44-A13 can optimize cholesterol metabolism and reduce its activity by inducing CYP7A1 expression. F44-A13 reduces levels of cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C) in mouse models. F44-A13 can be used in the study of metabolic diseases associated with lipid disorders .
|
-
- HY-113478S
-
|
Isotope-Labeled Compounds
|
Infection
Metabolic Disease
|
Ursodeoxycholic acid-2,2,4,4-d4 is the deuterium labeled Ursodeoxycholic acid (HY-13771). Ursodeoxycholic acid is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection[1][2][3][4][5].
|
-
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-76847
-
-
-
- HY-N3209
-
-
-
- HY-N3891
-
-
-
- HY-76847A
-
-
-
- HY-76847R
-
-
-
- HY-B0172
-
-
-
- HY-N0805
-
-
-
- HY-133890A
-
-
-
- HY-N4063
-
-
-
- HY-107738
-
Z/E-Guggulsterone
|
Triterpenes
Structural Classification
Classification of Application Fields
Terpenoids
Plants
Burseraceae
Disease Research Fields
Commiphora wightii
Cancer
|
Apoptosis
JNK
Akt
Caspase
FXR
Autophagy
|
Guggulsterone is a plant sterol derived from the gum resin of the tree Commiphora wightii. Guggulsterone inhibits the growth of a wide variety of tumor cells and induces apoptosis through down regulation of antiapoptotic gene products (IAP1, xIAP, Bfl-1/A1, Bcl-2, cFLIP and survivin), modulation of cell cycle proteins (cyclin D1 and c-Myc), activation of caspases and JNK, inhibition of Akt . Guggulsterone, a farnesoid X receptor (FXR) antagonist, decreases CDCA-induced FXR activation with IC50s of 17 and 15 μM for Z- and E-Guggulsterone, respectively .
|
-
-
- HY-N10640
-
-
-
- HY-N9933
-
-
-
- HY-110066
-
-
-
- HY-15371
-
-
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-76847S
-
|
Chenodeoxycholic Acid-d4 is the deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.
|
-
-
- HY-76847S2
-
|
Chenodeoxycholic acid- 13C is the 13C-labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.
|
-
-
- HY-76847S1
-
|
Chenodeoxycholic Acid-d9 is the deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.
|
-
-
- HY-76847S3
-
|
Chenodeoxycholic acid-d5 is the deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.
|
-
-
- HY-135400S
-
|
Glyco-obeticholic acid-d5 is the deuterium labeled Glyco-Obeticholic acid. Glyco-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is a farnesoid X receptor (FXR) agonist[1].
|
-
-
- HY-135399S
-
|
Tauro-obeticholic acid-d5 sodium is deuterium labeled Tauro-obeticholic acid. Tauro-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an orally bioavailable farnesoid-X receptor (FXR) agonist.
|
-
-
- HY-135103S
-
|
Tauro-β-muricholic acid-d4 (sodium) is the deuterium labeled Tauro-β-muricholic acid sodium. Tauro-β-muricholic Acid sodium (T-βMCA sodium), a endogenous metabolite, is a competitive and reversible farnesoid X receptor (FXR) antagonist, with an IC50 of 40 μM[1][2][3].
|
-
-
- HY-12222S
-
|
Obeticholic acid-d5 is the deuterium labeled Obeticholic acid. Obeticholic acid (INT-747) is a potent, selective and orally active FXR agonist with an EC50 of 99 nM. Obeticholic acid has anticholeretic and anti-inflammation effect. Obeticholic acid also induces autophagy[1][2][3].
|
-
-
- HY-12222S1
-
|
Obeticholic Acid-d4 is the deuterium labeled Obeticholic acid. Obeticholic acid (INT-747) is a potent, selective and orally active FXR agonist with an EC50 of 99 nM. Obeticholic acid has anticholeretic and anti-inflammation effect. Obeticholic acid also induces autophagy[1][2][3].
|
-
-
- HY-113478S
-
|
Ursodeoxycholic acid-2,2,4,4-d4 is the deuterium labeled Ursodeoxycholic acid (HY-13771). Ursodeoxycholic acid is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection[1][2][3][4][5].
|
-
Cat. No. |
Product Name |
Application |
Reactivity |
-
- HY-P81004
-
FXR1; FXR1P; hFXR1p
|
WB, IHC-P, ICC/IF, FC
|
Human, Mouse, Rat |
FXR1 Antibody is an unconjugated, approximately 70 kDa, rabbit-derived, anti-FXR1 monoclonal antibody. FXR1 Antibody can be used for: WB, IHC-P, ICC/IF, FC expriments in human, mouse, rat background without labeling.
|
-
- HY-P81224
-
Bile Acid Receptor NR1H4; BAR; FXR; Farnesoid X activated receptor; Farnesoid X receptor; Farnesoid X-activated receptor; Farnesol receptor HRR 1; Farnesol receptor HRR-1; Farnesol receptor HRR1; FXR; HRR 1; HRR1; NR1H4_HUMAN; Nuclear receptor subfamily 1 group H member 4; Retinoid X receptor interacting protein 14; Retinoid X receptor-interacting protein 14; RIP 14; RIP14; RXR interacting protein 14; RXR-interacting protein 14.
|
WB; ELISA; IHC-P; IHC-F; Flow-Cyt; ICC; IF
|
Human, Mouse(predicted: Rat, Dog, Pig, Cow, Horse, Sheep) |
NR1H4 Antibody is an unconjugated, approximately 56 kDa, rabbit-derived, anti-NR1H4 polyclonal antibody. NR1H4 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, ICC, IF expriments in human, mouse, and predicted: rat, dog, pig, cow, horse, sheep background without labeling.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: